Edwards Lifesciences (EW) stock price, revenue, and financials

Edwards Lifesciences market cap is $54.9 b, and annual revenue was $4.35 b in FY 2019

$54.9 B

EW Mkt cap, 20-Jan-2021

$1.1 B

Edwards Lifesciences Revenue Q3, 2020
Edwards Lifesciences Net income (Q3, 2020)325.2 M
Edwards Lifesciences EBIT (Q3, 2020)357.8 M

Edwards Lifesciences Revenue

Edwards Lifesciences revenue was $4.35 b in FY, 2019 which is a 16.8% year over year increase from the previous period.

Embed Graph

Edwards Lifesciences Revenue Breakdown

Embed Graph

Edwards Lifesciences revenue breakdown by business segment: 17.0% from Critical Care, 19.4% from Surgical Structural Heart, 63.0% from Transcatheter Aortic Valve Replacement and 0.6% from Other

Edwards Lifesciences revenue breakdown by geographic segment: 21.6% from Europe, 9.9% from Rest of World, 10.2% from Japan and 58.2% from United States

Edwards Lifesciences Income Statement

Annual

USDFY, 2017FY, 2018FY, 2019

Revenue

3.4b3.7b4.3b

Revenue growth, %

8%17%

Cost of goods sold

875.3m939.4m1.1b

Gross profit

2.6b2.8b3.2b

Gross profit Margin, %

75%75%74%

R&D expense

552.6m622.2m752.7m

General and administrative expense

984.7m1.1b1.2b

Operating expense total

1.5b2.0b2.1b

EBIT

748.2m1.1b

EBIT margin, %

20%26%

Interest expense

23.2m29.9m20.7m

Interest income

20.3m32.0m32.2m

Pre tax profit

1.0b761.4m1.2b

Income tax expense

451.3m39.2m119.6m

Net Income

583.6m722.2m1.0b

EPS

2.73.44.9

Edwards Lifesciences Balance Sheet

Annual

USDFY, 2017FY, 2018FY, 2019

Cash

818.3m714.1m1.2b

Accounts Receivable

421.6m456.9m543.6m

Prepaid Expenses

60.6m54.3m59.1m

Inventories

554.9m607.0m640.9m

Current Assets

2.5b2.3b3.0b

PP&E

679.7m867.5m1.1b

Goodwill

1.1b1.1b1.2b

Total Assets

5.7b5.3b6.5b

Accounts Payable

116.6m134.0m180.4m

Short-term debt

636.6m25.5m

Current Liabilities

1.4b876.6m902.4m

Long-term debt

438.4m593.8m653.3m

Total Debt

1.1b593.8m678.8m

Common Stock

212.0m215.2m218.1m

Additional Paid-in Capital

1.2b1.4b1.6b

Retained Earnings

2.0b2.7b3.7b

Total Equity

3.0b3.1b4.1b

Debt to Equity Ratio

0.4 x0.2 x0.2 x

Debt to Assets Ratio

0.2 x0.1 x0.1 x

Financial Leverage

1.9 x1.7 x1.6 x

Edwards Lifesciences Cash Flow

Annual

USDFY, 2017FY, 2018FY, 2019

Net Income

583.6m722.2m1.0b

Depreciation and Amortization

81.9m77.4m89.3m

Accounts Receivable

(3.9m)(28.7m)(88.0m)

Inventories

(124.0m)(65.7m)(105.4m)

Accounts Payable

85.2m192.5m(63.5m)

Cash From Operating Activities

1.0b926.8m1.2b

Purchases of PP&E

(168.1m)(238.7m)(254.4m)

Cash From Investing Activities

(647.2m)76.7m(595.8m)

Long-term Borrowings

(818.4m)(1.1b)(28.9m)

Cash From Financing Activities

(473.2m)(1.1b)(115.6m)

Net Change in Cash

(111.8m)(104.2m)465.0m

Interest Paid

19.9m30.1m19.9m

Income Taxes Paid

143.7m223.7m61.5m

Edwards Lifesciences Ratios

USDFY, 2017

EV/CFO

24.1 x

Revenue/Employee

281.6k

Debt/Equity

0.4 x

Debt/Assets

0.2 x

Financial Leverage

1.9 x

P/E Ratio

41.7

Edwards Lifesciences Operating Metrics

FY, 2017FY, 2018FY, 2019

Manufacturing Facilities

7 7 7

Patents and Patent Applications

3.60 k3.90 k4.70 k

Edwards Lifesciences Employee Rating

3.7682 votes
Culture & Values
3.9
Work/Life Balance
3.6
Senior Management
3.5
Salary & Benefits
4.1
Career Opportunities
3.7
Source